TY - JOUR
T1 - Detrimental actions of obesity-associated advanced glycation end-products on endometrial epithelial cell proliferation are alleviated by antioxidants
AU - Hutchison, Jennifer C.
AU - Evans, Jemma
AU - Edgell, Tracey A.
AU - Nie, Guiying
AU - Gardner, David K.
AU - Salamonsen, Lois A.
N1 - Funding Information:
This research was supported by the Victorian Government's Operational Infrastructure Support Program to the Hudson Institute of Medical Research . J.C.H. was supported by an Australian Government Research Training Program (RTP) Scholarship , and J.E. by a Fielding Foundation Fellowship . D.K.G. is supported by University of Melbourne .
Funding Information:
The authors are grateful to the patients who consented to the use of their endometrial tissues, their doctors and research nurse Judi Hocking for obtaining patient consent and collecting the tissue. The authors acknowledge Dr Shanti Gurung for technical advice and support, and the technical advice and facilities of Monash Histology Platform, Department of Anatomy, Monash University, and Monash Health Pathology. This research was supported by the Victorian Government's Operational Infrastructure Support Program to the Hudson Institute of Medical Research. J.C.H. was supported by an Australian Government Research Training Program (RTP) Scholarship, and J.E. by a Fielding Foundation Fellowship. D.K.G. is supported by University of Melbourne.
Publisher Copyright:
© 2023 Reproductive Healthcare Ltd.
PY - 2023/7
Y1 - 2023/7
N2 - Research question: Advanced glycation end-products (AGE) are elevated in the uterine environment of obese infertile women. Can the detrimental effects of AGE on endometrial epithelial cells be mitigated with therapeutics, and recapitulated in a more physiologically relevant primary model (organoids)? Design: Human endometrial epithelial cells (ECC-1) were exposed to AGE at concentrations physiologically representative of uterine fluid in lean or obese individuals, and three potential therapeutics: 25 nmol/l receptor for AGE (RAGE) antagonist FPS-ZM1, 100 μmol/l metformin, or a combination of antioxidants (10 μmol/l N-acetyl-L-cysteine, 10 μmol/l N-acetyl-L-carnitine and 5 μmol/l α-lipoic acid). Real-time cell analysis (xCELLigence, ACEA Biosciences) determined the rate of adhesion and proliferation. The proliferation of organoid-derived cells and secretion of cytokines from organoids was characterized in the presence of AGE (n = 5). The uterine fluid of women undergoing assisted reproduction was profiled for AGE-associated inflammatory markers (n = 77). Results: ECC-1 proliferation was reduced by AGE from obese versus lean conditions and vehicle control (P = 0.04 and P < 0.001, respectively), and restored to a proliferation corresponding to lean conditions by antioxidants. AGE influenced organoid derived primary endometrial epithelial cell proliferation in a donor-dependent manner. AGE increased the organoid secretion of the proinflammatory cytokine CXCL16 (P = 0.006). Clinically, CXCL16 correlated positively to maternal body mass index (R = 0.264, P = 0.021) and intrauterine glucose concentration (R = 0.736, P < 0.0001). Conclusions: Physiologically relevant concentrations of AGE alter endometrial epithelial cell function. Antioxidants restore the rate of proliferation of AGE-treated endometrial epithelial (ECC-1) cells. Primary endometrial epithelial cells, cultured as organoids, demonstrate altered proliferation and CXCL16 secretion in the presence of AGE equimolar with the uterine fluid from obese individuals.
AB - Research question: Advanced glycation end-products (AGE) are elevated in the uterine environment of obese infertile women. Can the detrimental effects of AGE on endometrial epithelial cells be mitigated with therapeutics, and recapitulated in a more physiologically relevant primary model (organoids)? Design: Human endometrial epithelial cells (ECC-1) were exposed to AGE at concentrations physiologically representative of uterine fluid in lean or obese individuals, and three potential therapeutics: 25 nmol/l receptor for AGE (RAGE) antagonist FPS-ZM1, 100 μmol/l metformin, or a combination of antioxidants (10 μmol/l N-acetyl-L-cysteine, 10 μmol/l N-acetyl-L-carnitine and 5 μmol/l α-lipoic acid). Real-time cell analysis (xCELLigence, ACEA Biosciences) determined the rate of adhesion and proliferation. The proliferation of organoid-derived cells and secretion of cytokines from organoids was characterized in the presence of AGE (n = 5). The uterine fluid of women undergoing assisted reproduction was profiled for AGE-associated inflammatory markers (n = 77). Results: ECC-1 proliferation was reduced by AGE from obese versus lean conditions and vehicle control (P = 0.04 and P < 0.001, respectively), and restored to a proliferation corresponding to lean conditions by antioxidants. AGE influenced organoid derived primary endometrial epithelial cell proliferation in a donor-dependent manner. AGE increased the organoid secretion of the proinflammatory cytokine CXCL16 (P = 0.006). Clinically, CXCL16 correlated positively to maternal body mass index (R = 0.264, P = 0.021) and intrauterine glucose concentration (R = 0.736, P < 0.0001). Conclusions: Physiologically relevant concentrations of AGE alter endometrial epithelial cell function. Antioxidants restore the rate of proliferation of AGE-treated endometrial epithelial (ECC-1) cells. Primary endometrial epithelial cells, cultured as organoids, demonstrate altered proliferation and CXCL16 secretion in the presence of AGE equimolar with the uterine fluid from obese individuals.
KW - Advanced glycation end-products
KW - Endometrium
KW - Epithelium
KW - Inflammation
KW - Obesity
KW - Organoids
UR - http://www.scopus.com/inward/record.url?scp=85154530931&partnerID=8YFLogxK
U2 - 10.1016/j.rbmo.2023.01.021
DO - 10.1016/j.rbmo.2023.01.021
M3 - Article
C2 - 37142478
AN - SCOPUS:85154530931
SN - 1472-6483
VL - 47
SP - 35
EP - 50
JO - Reproductive BioMedicine Online
JF - Reproductive BioMedicine Online
IS - 1
ER -